Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)

Clinical trial NCT07688980 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07688980
Sponsor: AstraZeneca
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus

Start date: 2026-10-30
Primary completion: 2029-04-13
Enrollment: 92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.